Patents by Inventor Ivan Bieche

Ivan Bieche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of biomarkers for detecting and evaluating a hepatic fibrosis
    Patent number: 12110551
    Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
    Type: Grant
    Filed: December 28, 2021
    Date of Patent: October 8, 2024
    Assignees: BIO-RAD EUROPE GMBH, ARIANA PHARMACEUTICALS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Bénédicte Watelet, Tarik Asselah, Ivan Bieche, Isabelle Catherine Batxelli, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Daniel Laune, Mohammad Afshar, Eve Mathieu Dupas
  • COMBINATION OF BIOMARKERS FOR DETECTING AND EVALUATING A HEPATIC FIBROSIS
    Publication number: 20220205039
    Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
    Type: Application
    Filed: December 28, 2021
    Publication date: June 30, 2022
    Inventors: BÉNÉDICTE WATELET, TARIK ASSELAH, IVAN BIECHE, ISABELLE CATHERINE BATXELLI, NATHALIE JULLIAN, MICHEL VIDAUD, PATRICK MARCELLIN, DANIEL LAUNE, MOHAMMAD AFSHAR, EVE LAURE MATHIEU
  • COMBINATION OF BIOMARKERS FOR DETECTING AND EVALUATING A HEPATIC FIBROSIS
    Publication number: 20200056235
    Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
    Type: Application
    Filed: August 28, 2019
    Publication date: February 20, 2020
    Inventors: BÉNÉDICTE WATELET, TARIK ASSELAH, IVAN BIECHE, ISABELLE CATHERINE BATXELLI, NATHALIE JULLIAN, MICHEL VIDAUD, PATRICK MARCELLIN, DANIEL LAUNE, MOHAMMAD AFSHAR, EVE LAURE MATHIEU
  • Combination of biomarkers for detecting and evaluating a hepatic fibrosis
    Patent number: 10435744
    Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: October 8, 2019
    Assignees: BIO-RAD EUROPE GMBH, ARIANA PHARMACEUTICALS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Bénédicte Watelet, Tarik Asselah, Ivan Bieche, Isabelle Catherine Batxelli, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Daniel Laune, Mohammad Afshar, Eve Laure Mathieu
  • Combination of biomarkers for the prognosis of response or non-response to an anti-HCV treatment
    Patent number: 9879320
    Abstract: The application concerns means for predicting whether a subject infected with one or more HCVs has a high probability of responding to an anti-HCV treatment which will comprise the administration of interferon and of ribavirin or whether, in contrast, that subject has a high probability of not responding to that anti-HCV treatment. The means of the invention in particular involve assaying the levels of expression of selected genes, said selected genes being: at least one gene from among MBL2, LGALS3BP and IL8, and at least one gene from among G1P2, CCL21 and CXCL10, and optionally, at least one gene from among AFP, CRP, CXCL11, CXCL6, CXCL9, FGF7, MDK, MMP2, SFN, TGFB2 and VEGFD.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: January 30, 2018
    Inventors: Ivan Bieche, Bénédicte Watelet, Tarik Asselah, Isabelle Catherine Batxelli, Eve Laure Mathieu, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Mohammad Afshar
  • COMBINATION OF BIOMARKERS FOR DETECTING AND EVALUATING A HEPATIC FIBROSIS
    Publication number: 20170283871
    Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
    Type: Application
    Filed: April 17, 2017
    Publication date: October 5, 2017
    Inventors: BÉNÉDICTE WATELET, TARIK ASSELAH, IVAN BIECHE, ISABELLE CATHERINE BATXELLI, NATHALIE JULLIAN, MICHEL VIDAUD, PATRICK MARCELLIN, DANIEL LAUNE, MOHAMMAD AFSHAR, EVE LAURE MATHIEU
  • Combination of biomarkers for the detection and evaluation of hepatitis fibrosis
    Patent number: 9624541
    Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: April 18, 2017
    Assignees: BIO-RAD INNOVATIONS, ARIANA PHARMACEUTICALS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Bénédicte Watelet, Tarik Asselah, Ivan Bieche, Isabelle Catherine Batxelli, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Daniel Laune, Mohammad Afshar, Eve Laure Mathieu
  • PROGNOSIS FOR GLIOMA
    Publication number: 20150038357
    Abstract: Disclosed is a method of determining the survival prognosis of a patient afflicted by a glioma. The method includes assessing the level of expression of one or more specific gene in cells of the glioma.
    Type: Application
    Filed: October 1, 2012
    Publication date: February 5, 2015
    Inventors: Dominique Joubert, Luc Bauchet, Jean-Philippe Hugnot, Ivan Bieche, Rosette Lidereau, Thierry Reme, Hugues Duffau, Valerie Rigau
  • NKX2.2 INHIBITORS AS DRUGS
    Publication number: 20140005249
    Abstract: The present invention relates to NKX2.2 inhibitors such as shRNAs for treating pathologies.
    Type: Application
    Filed: July 21, 2011
    Publication date: January 2, 2014
    Applicants: UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Jean-Philippe Hugnot, Pierre-Olivier Guichet, Marisa Teigell, Ivan Bieche, Rosette Lidereau, Dominique Joubert, Luc Bauchet, Valerie Rigau
  • COMBINATION OF BIOMARKERS FOR THE DETECTION AND EVALUATION OF HEPATITIS FIBROSIS
    Publication number: 20130323720
    Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
    Type: Application
    Filed: February 9, 2012
    Publication date: December 5, 2013
    Applicant: BIO RAD INNOVATIONS
    Inventors: Bénédicte Watelet, Tarik Asselah, Ivan Bieche, Isabelle Catherine Batxelli, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Daniel Laune, Mohammad Afshar, Eve Laure Mathieu
  • COMBINATION OF BIOMARKERS FOR THE PROGNOSIS OF RESPONSE OR NON-RESPONSE TO AN ANTI-HCV TREATMENT
    Publication number: 20130316332
    Abstract: The application concerns means for predicting whether a subject infected with one or more HCVs has a high probability of responding to an anti-HCV treatment which will comprise the administration of interferon and of ribavirin or whether, in contrast, that subject has a high probability of not responding to that anti-HCV treatment. The means of the invention in particular involve assaying the levels of expression of selected genes, said selected genes being: at least one gene from among MBL2, LGALS3BP and IL8, and at least one gene from among G1P2, CCL21 and CXCL10, and optionally, at least one gene from among AFP, CRP, CXCL11, CXCL6, CXCL9, FGF7, MDK, MMP2, SFN, TGFB2 and VEGFD.
    Type: Application
    Filed: February 9, 2012
    Publication date: November 28, 2013
    Applicants: BIO-RAD INNOVATIONS, ARIANA PHARMACEUTICALS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Ivan Bieche, Bénédicte Watelet, Tarik Asselah, Isabelle Catherine Batxelli, Eve Laure Mathieu, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Mohammad Afshar
  • METHODS AND KITS FOR DETERMINING DRUG SENSITIVITY IN PATIENTS INFECTED WITH HCV
    Publication number: 20100183555
    Abstract: An in vitro method for determining whether a patient infected with HCV is a responder or non-responder to the treatment with interferon-alpha and ribavirin. More specifically, the method includes a step of determining the expression level of the IFI27, CXCL9 and G1P2 genes in a biological sample.
    Type: Application
    Filed: February 4, 2008
    Publication date: July 22, 2010
    Applicants: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE RENE DESCARTES (PARIS V), UNIVERSITE PARIS 7 - DENIS DIDEROT
    Inventors: Michel Vidaud, Ivan Bieche, Tarik Asselah, Patrick Marcellin